Gale Smith - Researcher Profile | RDL Research Database

Publications

3 shown

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech , Gary Albert , Iksung Cho +26 more

At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell res...

2020 New England Journal of Medicine 1219 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

The bidirectional transfer of DNA and RNA to nitrocellulose or diazobenzyloxymethyl-paper

Gale Smith , Max D. Summers

1980 Analytical Biochemistry 756 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 2,213
Institution: Baylor College of Medicine

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6482-6026

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.